ETON
Eton Pharmaceuticals, Inc.
$31.59
-1.62%
$865.3M
No data for this timeframe.
Vol
Market Cap$865.3M
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (89%)
Inst. Holders50 funds
Inst. Value$157.8M
Inst. Activity4 buys / 4 sells
Insider Activity0B / 4S
Insider Net $-$6.7M
SEC Reports8
Press Releases3
Recent Activity
May 29, 2026
SEC
Eton Pharmaceuticals CEO Sean Brynjelsen sold $3.82M worth of stock and CBO David Krempa sold $1.80M (including derivati
CLUSTER — Impact 5/10
May 28, 2026
SEC
CEO Sean Brynjelsen filed a Form 144 indicating intent to sell 120,000 common shares valued at approximately $3.89 milli
144 — Impact 5/10
May 28, 2026
Insider
BRYNJELSEN SEAN sold 119,852 shares
President & CEO @ $31.88 ($3.8M)
May 27, 2026
Insider
Krempa David acquired via exercise 12,476 shares
Chief Business Officer @ $1.37 ($17.1K)
May 27, 2026
Insider
Krempa David sold 19,679 shares
Chief Business Officer @ $31.47 ($619.4K)
May 19, 2026
SEC
Eton Pharmaceuticals entered into a supply and distribution agreement for exclusive U.S. commercialization rights to IMP
8-K — Impact 6/10
Inst.
Woodline Partners LP — ADD
170,699 shares ($4.2M)
Inst.
BANK OF AMERICA CORP — ADD
144,367 shares ($3.6M)
Price Targets
$45.67
+44.6% upside
Strong Buy
Current $31.59
Low $40.00
Median $40.00
High $57.00
3 analysts
$40.00
$57.00
Analyst Ratings
2Strong Buy
6Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 15, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| Mar 20, 2026 | B. Riley Securities | MAINTAIN | Buy → Buy |
| Mar 20, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| Mar 20, 2026 | Craig-Hallum | MAINTAIN | Buy → Buy |
| Mar 3, 2026 | Craig-Hallum | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $0.19 ▼ -5.0% | $0.19 — $0.19 | 533% YoY | 1 |
| Next Q | $0.31 ▲ +34.8% | $0.31 — $0.31 | 675% YoY | 1 |
| Current FY | $1.01 ▲ +20.2% | $1.01 — $1.01 | 216% YoY | 1 |
| Next FY | $1.88 ▲ +20.5% | $1.88 — $1.88 | 86% YoY | 1 |
Latest Reports
BEARISH
CLUSTER
5/10
Eton Pharmaceuticals CEO Sean Brynjelsen sold $3.82M worth of stock and CBO David Krempa sold $1.80M (including derivati
May 29, 2026
BEARISH
144
5/10
CEO Sean Brynjelsen filed a Form 144 indicating intent to sell 120,000 common shares valued at approximately $3.89 milli
May 28, 2026
MIXED
Press
5/10
Eton Pharmaceuticals has dosed the first patient in a pilot clinical study evaluating ET-700, its extended-release zinc
Apr 27, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| ROYAL BANK OF CANADA | — | DOUBLED |
| BlackRock, Inc. | $42.4M | — |
| VANGUARD CAPITAL MANAGEMENT LLC | $24.5M | — |
| STATE STREET CORP | $13.1M | ADD |
| National Philanthropic Trust | $12.1M | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 28, 2026 | BRYNJELSEN SEAN | SELL | $3.8M |
| May 27, 2026 | Krempa David | M | $17.1K |
| May 27, 2026 | Krempa David | SELL | $619.4K |
| May 26, 2026 | Krempa David | M | $34.5K |
| May 26, 2026 | Krempa David | SELL | $1.2M |
50 institutional holders with $157.8M total value (6,394,563 shares) as of 2026-Q1. Top holders: ROYAL, BlackRock,, VANGUARD.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | ROYAL BANK OF CANADA | 13 | $0.00 | 0.0% | DOUBLED +210.9% |
| 2 | BlackRock, Inc. | 1,717,286 | $42.4M | 26.9% | — |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 994,089 | $24.5M | 15.5% | — |
| 4 | STATE STREET CORP | 530,215 | $13.1M | 8.3% | ADD +35.7% |
| 5 | National Philanthropic Trust | 492,112 | $12.1M | 7.7% | — |
| 6 | MORGAN STANLEY | 477,957 | $11.8M | 7.5% | DOUBLED +1016.7% |
| 7 | GOLDMAN SACHS GROUP INC | 217,446 | $5.4M | 3.4% | — |
| 8 | Woodline Partners LP | 170,699 | $4.2M | 2.7% | ADD +78.8% |
| 9 | VANGUARD FIDUCIARY TRUST CO | 164,715 | $4.1M | 2.6% | — |
| 10 | RENAISSANCE TECHNOLOGIES LLC | 163,321 | $4.0M | 2.6% | TRIM -36.6% |
| 11 | VANGUARD PORTFOLIO MANAGEMENT LLC | 151,748 | $3.7M | 2.4% | — |
| 12 | BANK OF AMERICA CORP /DE/ | 144,367 | $3.6M | 2.3% | ADD +37.8% |
| 13 | CITADEL ADVISORS LLC | 107,815 | $2.7M | 1.7% | — |
| 14 | TWO SIGMA INVESTMENTS, LP | 106,393 | $2.6M | 1.7% | TRIM -73.3% |
| 15 | MARSHALL WACE, LLP | 82,721 | $2.0M | 1.3% | ADD +75.3% |
| 16 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 79,600 | $2.0M | 1.2% | — |
| 17 | WELLINGTON MANAGEMENT GROUP LLP | 70,124 | $1.7M | 1.1% | DOUBLED +202.0% |
| 18 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 68,795 | $1.7M | 1.1% | DOUBLED +487.7% |
| 19 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 66,100 | $1.6M | 1.0% | — |
| 20 | SEI INVESTMENTS CO | 58,034 | $1.4M | 0.9% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| Woodline Partners LP | ADD | 95,487 | 170,699 | +78.8% | $4.2M | 2026-Q1 |
| BANK OF AMERICA CORP /DE/ | ADD | 104,796 | 144,367 | +37.8% | $3.6M | 2026-Q1 |
| Connor, Clark & Lunn Investment Management Ltd. | TRIM | 76,586 | 42,693 | -44.3% | $1.1M | 2026-Q1 |
| LOS ANGELES CAPITAL MANAGEMENT LLC | TRIM | 14,631 | 10,269 | -29.8% | $253.4K | 2026-Q1 |
| Russell Investments Group, Ltd. | NEAR_EXIT | 49,694 | 2,670 | -94.6% | $65.9K | 2026-Q1 |
| FMR LLC | TRIM | 3,076 | 1,519 | -50.6% | $37.5K | 2026-Q1 |
| PNC FINANCIAL SERVICES GROUP, INC. | DOUBLED | 51 | 179 | +251.0% | $4.4K | 2026-Q1 |
| CWM, LLC | DOUBLED | 26 | 107 | +311.5% | $2.6K | 2026-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 324,621 | 205,700 | -36.6% | $3.5M | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | ADD | 74,657 | 104,796 | +40.4% | $1.8M | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 286,421 | 76,602 | -73.3% | $1.3M | 2025-Q4 |
| Connor, Clark & Lunn Investment Management Ltd. | TRIM | 143,811 | 76,586 | -46.7% | $1.3M | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 16,709 | 28,293 | +69.3% | $478.4K | 2025-Q4 |
| Invesco Ltd. | ADD | 13,478 | 19,691 | +46.1% | $333.0K | 2025-Q4 |
| FMR LLC | TRIM | 5,694 | 3,076 | -46.0% | $52.0K | 2025-Q4 |
| GROUP ONE TRADING LLC | TRIM | 762 | 500 | -34.4% | $8.5K | 2025-Q4 |
| PNC FINANCIAL SERVICES GROUP, INC. | DOUBLED | 17 | 51 | +200.0% | $862.00 | 2025-Q4 |
| STATE STREET CORP | ADD | 323,194 | 438,445 | +35.7% | $9.5M | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | ADD | 214,552 | 286,421 | +33.5% | $6.2M | 2025-Q3 |
| Connor, Clark & Lunn Investment Management Ltd. | TRIM | 222,083 | 143,811 | -35.2% | $3.1M | 2025-Q3 |
| WELLINGTON MANAGEMENT GROUP LLP | DOUBLED | 29,213 | 88,219 | +202.0% | $1.9M | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 36,921 | 74,657 | +102.2% | $1.6M | 2025-Q3 |
| Russell Investments Group, Ltd. | DOUBLED | 18,112 | 54,865 | +202.9% | $1.2M | 2025-Q3 |
| ENVESTNET ASSET MANAGEMENT INC | TRIM | 23,050 | 11,377 | -50.6% | $247.2K | 2025-Q3 |
| FMR LLC | DOUBLED | 455 | 5,694 | +1151.4% | $123.7K | 2025-Q3 |
3 unique insiders with 10 transactions. Net insider value: -$6.7M ($0.00 bought, $6.7M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 28, 2026 | BRYNJELSEN SEAN | President & CEO | SELL | 119,852 | $31.88 | $3.8M |
| May 27, 2026 | Krempa David | Chief Business Officer | EXERCISE | 12,476 | $1.37 | $17.1K |
| May 27, 2026 | Krempa David | Chief Business Officer | SELL | 19,679 | $31.47 | $619.4K |
| May 26, 2026 | Krempa David | Chief Business Officer | EXERCISE | 25,000 | $1.38 | $34.5K |
| May 26, 2026 | Krempa David | Chief Business Officer | SELL | 37,524 | $31.49 | $1.2M |
| May 22, 2026 | Krempa David | Chief Business Officer | EXERCISE | 30,591 | $3.58 | $109.5K |
| May 22, 2026 | Krempa David | Chief Business Officer | SELL | 32,963 | $33.22 | $1.1M |
| Apr 21, 2026 | RIEDEL NORBERT G | Director | EXERCISE | 12,500 | $7.31 | $91.4K |
| Feb 3, 2026 | RIEDEL NORBERT G | Director | EXERCISE | 30,000 | $4.42 | $132.6K |
| Feb 3, 2026 | RIEDEL NORBERT G | Director | EXERCISE | 30,000 | — | — |
8 SEC filing reports analyzed. Sentiment: 3 bullish, 2 bearish, 0 mixed, 3 neutral. Avg impact: 5.1/10.
BEARISH
CLUSTER
5/10
Eton Pharmaceuticals CEO Sean Brynjelsen sold $3.82M worth of stock and CBO David Krempa sold $1.80M
May 29, 2026
BEARISH
144
5/10
CEO Sean Brynjelsen filed a Form 144 indicating intent to sell 120,000 common shares valued at appro
May 28, 2026
BULLISH
8-K
6/10
Eton Pharmaceuticals entered into a supply and distribution agreement for exclusive U.S. commerciali
May 19, 2026
NEUTRAL
8-K
4/10
Eton Pharmaceuticals announced the initiation of a pilot clinical study for its product candidate ET
Apr 27, 2026
NEUTRAL
8-K
3/10
Eton Pharmaceuticals announced the appointment of Judith Matthews as CFO, effective June 1, 2026, su
Apr 16, 2026
NEUTRAL
8-K
4/10
Eton Pharmaceuticals amended its credit agreement with SWK Funding LLC to extend the interest-only p
Apr 15, 2026
BULLISH
INST-CLUSTER
6/10
Three major passive institutions — Morgan Stanley, Wells Fargo, and UBS — significantly increased th
Feb 28, 2026
BULLISH
8-K
8/10
Eton Pharmaceuticals received FDA approval for DESMODA (desmopressin acetate) Oral Solution, the fir
Feb 25, 2026
MIXED
5/10
Eton Pharmaceuticals has dosed the first patient in a pilot clinical study evaluating ET-700, its ex
Apr 27, 2026
NEUTRAL
3/10
Eton Pharmaceuticals announced it will report its fourth quarter and full year 2025 financial result
Mar 3, 2026
BULLISH
7/10
Eton Pharmaceuticals has in-licensed U.S. commercialization rights to HEMANGEOL®, the only FDA-appro
Mar 2, 2026
Current analyst consensus: Strong Buy (89% buy). Based on 9 analysts: 2 strong buy, 6 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$45.67 mean target
+44.6% upside
Strong Buy (3.00)
$40.00 Low
$57.00 High
| Metric | Value |
|---|---|
| Current Price | $31.59 |
| Target Low | $40.00 |
| Target Mean | $45.67 |
| Target Median | $40.00 |
| Target High | $57.00 |
| # Analysts | 3 |
| Recommendation | Strong Buy (3.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$0.19 | $0.19 | $0.19 | 533.3% | -5.0% | 0↑ 1↓ | $0.0B | 42.0% | 1 |
| Next Q 2026-09-30 |
$0.31 | $0.31 | $0.31 | 675.0% | +34.8% | 1↑ 0↓ | $0.0B | 40.2% | 1 |
| Current FY 2026-12-31 |
$1.01 | $1.01 | $1.01 | 215.6% | +20.2% | 1↑ 0↓ | $0.1B | 50.7% | 1 |
| Next FY 2027-12-31 |
$1.88 | $1.88 | $1.88 | 86.1% | +20.5% | 1↑ 0↓ | $0.2B | 51.4% | 1 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $0.190 | |
| 7d ago | $0.200 | -0.010 |
| 30d ago | $0.200 | -0.010 |
| 60d ago | $0.200 | -0.010 |
| 90d ago | $0.230 | -0.040 |
3 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 15, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Mar 20, 2026 | B. Riley Securities | MAINTAIN | Buy | Buy |
| Mar 20, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Mar 20, 2026 | Craig-Hallum | MAINTAIN | Buy | Buy |
| Mar 3, 2026 | Craig-Hallum | MAINTAIN | Buy | Buy |
| Mar 2, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% | |
| May 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% | |
| Apr 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% | |
| Mar 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% | |
| Feb 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% | |
| Jan 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 19, 2026
other
Eton Pharmaceuticals Expands Rare Disease Portfolio Through Agreement for U.S. Commercialization Rights to IMPAVIDO® (miltefosine)
<p align="left"><br>DEER PARK, Ill., May 19, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovat
May 14, 2026
earnings_calendar
ETON Q1 2026 Earnings Scheduled — 2026-05-14
May 12, 2026
other
Eton Pharmaceuticals to Participate in Upcoming Investor Conferences
<p align="left">DEER PARK, Ill., May 12, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton” or the “Company”) (Nasdaq: ETON), an innovative
May 11, 2026
earnings_calendar
ETON Q1 2026 Earnings Scheduled — 2026-05-11
May 7, 2026
earnings_calendar
ETON Q1 2026 Earnings Scheduled — 2026-05-07
May 1, 2026
other
Eton Pharmaceuticals relaunches HEMANGEOL® (propranolol) Oral Solution with Eton Cares and Exclusive Specialty Pharmacy Distribution
<p>DEER PARK, Ill., May 01, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutica
Apr 27, 2026
fda
Eton Pharmaceuticals Announces Initiation of Clinical Study for Product Candidate ET-700
-- Company’s extended-release formulation of zinc acetate will be compared to GALZIN® (zinc acetate) and a placebo for the treatment of Wilson disease
Apr 16, 2026
other
Eton Pharmaceuticals Announces CFO Succession Plan
Experienced pharmaceutical executive Judith M. Matthews to assume CFO role on June 1st <pre>Experienced pharmaceutical executive Judith M. Matthews to
Mar 19, 2026
earnings
Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
<p>DEER PARK, Ill., March 19, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceuti
Mar 19, 2026
earnings_calendar
ETON Q4 2025 Earnings After Market Close — 2026-03-19
Mar 12, 2026
earnings_calendar
ETON Q4 2025 Earnings After Market Close — 2026-03-12
Mar 3, 2026
earnings
Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, March 19, 2026
<p>DEER PARK, Ill., March 03, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceuti
Mar 2, 2026
m_and_a
Eton Pharmaceuticals Expands Rare Disease Portfolio Through Acquisition of U.S. Commercialization Rights to HEMANGEOL® (propranolol hydrochloride) Oral Solution
<p>DEER PARK, Ill., March 02, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceuti